



**IQVIA Contact:**

Tor Constantino  
Global Media and External Affairs, Lead  
tor.constantino@iqvia.com  
(484) 567-6732



**CIBMTR Contact:**

Liz Siepmann,  
Communications Specialist  
esiepmann@mcw.edu  
(414) 805-0665

**CIBMTR<sup>®</sup> announces real world data effort to accelerate breakthroughs that transform patient experiences in cellular therapy with IQVIA**

**Minneapolis, MN, and Durham, NC, February 19, 2020** – The CIBMTR<sup>®</sup> (Center for International Blood and Marrow Transplant Research<sup>®</sup>) today announced the selection of IQVIA as it seeks to expand the value real world data can bring to patients, through systematic investigation to generate real world evidence. IQVIA (NYSE: IQV) is a company known worldwide for its expertise in building technology solutions customized for global research networks engaged in complex data exchange for clinical outcomes registries.

The CIBMTR is a long-standing research collaboration between the National Marrow Donor Program<sup>®</sup> (NMDP)/Be The Match<sup>®</sup> and the Medical College of Wisconsin (MCW), dedicated to improving survival, treatment and quality of life for transplant and cellular therapy patients. The engagement with IQVIA will enable accelerated progress towards a shared vision to optimize real world data for the benefit of providers, potential bone marrow donors and recipients, and other stakeholders.

“Through this initiative, the CIBMTR will strengthen its position in collecting timely, high-quality data and driving data standards wherever possible to accelerate discovery and new frontiers in precision medicine and real world evidence,” said India Hook-Barnard, PhD, Senior Vice President, Patient Outcomes & Experience, NMDP/Be The Match and CIBMTR.

Together, the parties will create a real world data acquisition capability that will transform the ability of the CIBMTR to collect data from its global network partners. In addition, extensive metadata development is planned to generate specified information to improve the accessibility and efficiency of tracking and manipulating data throughout analyses.

“The field of transplantation medicine and cellular therapy is growing exponentially. Data technologies must keep pace to support patient needs through data optimization. Human lives are at stake,” said Jon Morris, MD, Vice President & General Manager,

Healthcare Solutions, IQVIA. “We are excited to bring our unique expertise and experience, technology and data networks to an organization that is mission-driven and patient-focused.”

Mary Horowitz, MD, Chief Scientific Director, CIBMTR, and Robert A. Uihlein, Jr., Professor of Hematologic Research, MCW, added: “CIBMTR’s strategic initiative to invest in a forward-looking data strategy that enlists the experience and expertise of IQVIA underscores our commitment to serve the public good through an unparalleled data outcomes resource that unites the global scientific community.”

**###**

### **About the CIBMTR**

The [CIBMTR](#)<sup>®</sup> (Center for International Blood and Marrow Transplant Research<sup>®</sup>) is a research collaboration between the National Marrow Donor Program<sup>®</sup> (NMDP)/Be The Match<sup>®</sup> and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database.

For more information on the CIBMTR, please visit [www.cibmtr.org](http://www.cibmtr.org) or follow the CIBMTR on [Facebook](#), [LinkedIn](#), or Twitter at [@CIBMTR](#).

### **About IQVIA**

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper

understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit [www.iqvia.com](http://www.iqvia.com).

### **About the National Marrow Donor Program/Be The Match**

The National Marrow Donor Program® (NMDP)/Be The Match® is the global leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia and lymphoma, as well as other diseases. The NMDP/Be The Match manages the world's largest registry of potential blood stem cell donors and cord blood units, connects patients to their donor match for a life-saving marrow or umbilical cord blood transplant and educates health care professionals and patients. In 2016, the NMDP/Be The Match established [Be The Match BioTherapies](#)® to accelerate patient access to life-saving therapies, by providing proven services and support to companies developing and delivering cell and gene therapies.

Learn more at [BeTheMatchClinical.org](http://BeTheMatchClinical.org).

### **About the Medical College of Wisconsin**

With a history dating back to 1893, The Medical College of Wisconsin is dedicated to leadership and excellence in education, patient care, research and community engagement. More than 1,200 students are enrolled in MCW's medical school and graduate school programs in Milwaukee, Green Bay, and Central Wisconsin in 2016. MCW's School of Pharmacy opened in 2017. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In FY2016, faculty received more than \$184 million in external support for research, teaching, training and related purposes. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,500 physicians provide care in virtually every specialty of medicine for more than 525,000 patients annually.